Enanta Pharmaceuticals Inc (ENTA)

[TREND1]

Enanta expects that its current cash, cash equivalents and marketable securities will be sufficient to meet the anticipated cash requirements of its existing business and development programs for the foreseeable future.



Financial Guidance for Fiscal Year Ending September 30, 2018

• Research and development expense between $90 million and $110 million
• General and administration expense between $22 million and $28 million


Net income for the three months ended September 30, 2017 was $36.5 million, or $1.86 per diluted common share, compared to a net loss of $1.8 million, or $(0.09) per diluted common share, for the corresponding period in 2016.

For the twelve months ended September 30, 2017, net income was $17.7 million, or $0.91 per diluted common share, compared to net income of $21.7 million, or $1.13 per diluted common share, for the corresponding period in 2016.


source current report